DYN
Dyne Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.28
−2.69%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.4x
Market Cap
$4.53B
MomentumView details →
1D Return
−2.69%
YTD Return
+24.74%
RSI (14)
41.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.4x
Market Cap
$4.53B
RSI (14)
41.2
MomentumView details →
1D Return
−2.69%
YTD Return
+24.74%
SummaryUpdated Jun 1, 2026
Dyne Therapeutics, Inc. (NASDAQ:DYN) is a clinical-stage biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts. The company went public in September 2020 and focuses exclusively on developing innovative therapeutics for genetically driven muscle diseases. Dyne operates as a specialized muscle disease company, leveraging its proprietary FORCE platform technology to advance potential treatments for rare and devastating muscular conditions that currently have limited or no therapeutic options.
Similar companies
Latest newsMore news →
Dyne Therapeutics received U.S. FDA clearance of its Investigational New Drug application for DYNE-302 in facioscapulohumeral muscular dystrophy.38d agoDyne Therapeutics priced an upsized underwritten public offering of 18,300,000 shares of common stock at $20.50 per share, expecting gross proceeds of $375,150,000.40d agoThe U.S. FDA accepted for review the Biologics License Application for Dyne Therapeutics' z-rostudirsen for Duchenne muscular dystrophy amenable to exon 51 skipping, granting priority review with a PDUFA target action date of January 21, 2027.46d ago